Clinical Trial Detail

NCT ID NCT01399918
Title Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

renal cell carcinoma

Therapies

Bevacizumab + Everolimus

Age Groups: adult

No variant requirements are available.